Latest Breaking News On - Enliven therapeutics inc - Page 8 : vimarsana.com

North American Morning Briefing: China Angst -2-

R&D spending drove increased Enliven Therapeutics loss in Q2 – BizWest

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

North American Morning Briefing : Sentiment Hit by -2- - Today at 06:21 am

Easterly Government Properties is expected to report for 2Q. EnPro Industries Inc is expected to report $1.13 for 2Q. Enliven Therapeutics Inc is expected to report for 2Q. ...

Comparing Enliven Therapeutics (NASDAQ:ELVN) & Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT – Get Free Report) and Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Institutional and Insider Ownership 73.1% of Abbott Laboratories […]

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down to $19.05

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $19.05, but opened at $17.83. Enliven Therapeutics shares last traded at $17.84, with a volume of 1,186 shares trading hands. Enliven Therapeutics Trading Up 1.0 % The business has a fifty […]

Enliven Therapeutics (NASDAQ:ELVN) Trading Down 3.2%

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3.2%

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price dropped 3.2% on Monday . The stock traded as low as $18.11 and last traded at $18.11. Approximately 9,621 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 146,586 shares. The stock had previously closed at $18.70. Enliven […]

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 3.5%

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Up 29.4% in June

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 3,830,000 shares, an increase of 29.4% from the May 31st total of 2,960,000 shares. Based on an average daily trading volume, of 228,300 shares, the days-to-cover ratio […]